Related Experiment Video
Updated: Feb 6, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
Published on: May 2, 2013
Valproic acid regulates Ang II-induced pericyte-myofibroblast trans-differentiation via MAPK/ERK pathway
Yan Zhang1,2, Feng Gao2,3, Yuan Tang1
1Department of Cardiology, Affiliated Fuzhou First Hospital of Fujian Medical University Fujian, China.
Abstract:
Myocardial fibrosis (MF) plays an important part in cardiovascular diseases. The main cytological characteristics of MF is the increased number of myofibroblasts, which have multiple sources such as EMT, EndMT, myeloid progenitors, monocytes, and fibrocytes. Recent data showed that pericytes may represent a major source of myofibroblasts in kidney fibrosis. Valproic acid (VPA) is a kind of short-chain fatty acid. It was reported in recent studies that VPA regulates gene expression and influences various signal pathways. HDACs inhibitors can hinder the growth of tumor cells and differentiation of stem cells. And little is known about the effects of HDACs inhibitors on myofibroblasts transdiffererntiaton. This study focused on the role of HDACs in pericyte-myofibroblast trans-differentiation and how HDACs inhibitor VPA influenced proliferation, migration, viability and myofibroblast trans-differentiation of pericytes for the first time. Rat cardiac fibrosis model was induced by Ang II. Immunohistochemistry was employed to examine cardiac fibrosis and flow cytometry was used to analyze whether inflammatory cells involve VPA-induced trans-differentiation. Pericytes proliferation, migration and differentiation to myofibroblasts were performed to examine the role of VPA on pericyte trans-differentiation. Immunoblot and qPCR were applied to identify the signal transduction involving in VPA-induced trans-differentiation. In vivo study showed that HDAC inhibitor VPA blocks cardiac fibrosis, and inflammation inhibition was not involved in this process. VPA treatment inhibited Ang II pericyte proliferation, migration and transdifferentiation to myofibroblast. Furthermore, the inhibition of α-SMA expression by VPA was related to reduce phosphorylation of ERK, and a pharmacological inhibitor of MEK suppressed Ang II-induced α-SMA expression. HDAC4 knockdown resulted in inhibiting Ang II-mediated α-SMA expression as well as the phosphorylation of ERK. Moreover, the inhibitors of protein phosphatase 2A and 1 (PP2A and PP1) restored the Ang II-stimulated α-SMA expression from the inhibitory effect of VPA. Together, the current data indicate that the differentiation of pericytes to myofibroblasts is HDAC4 dependent and requires phosphorylation of ERK.
Insights
Valproic acid (VPA), a histone deacetylase (HDAC) inhibitor, effectively blocks cardiac fibrosis by inhibiting pericyte-myofibroblast transdifferentiation. This process is dependent on HDAC4 and ERK phosphorylation, offering a novel therapeutic target for cardiovascular diseases.
Area of Science:
- Cardiovascular Biology
- Cellular Biology
- Pharmacology
Background:
- Myocardial fibrosis (MF) is a key factor in cardiovascular diseases, characterized by increased myofibroblasts from various cellular sources.
- Pericytes are emerging as a significant source of myofibroblasts in fibrotic conditions.
- Histone deacetylase (HDAC) inhibitors, like valproic acid (VPA), have shown effects on cell differentiation, but their role in myofibroblast transdifferentiation is largely unknown.
Purpose of the Study:
- To investigate the role of HDACs in pericyte-myofibroblast transdifferentiation.
- To determine the effects of the HDAC inhibitor VPA on pericyte proliferation, migration, viability, and transdifferentiation.
- To elucidate the signaling pathways involved in VPA-modulated pericyte transdifferentiation.
Main Methods:
- Established a rat cardiac fibrosis model induced by Angiotensin II (Ang II).
- Utilized immunohistochemistry for fibrosis assessment and flow cytometry for inflammatory cell analysis.
- Assessed pericyte proliferation, migration, and differentiation; employed immunoblot and qPCR to identify signaling pathways.
Main Results:
- VPA treatment inhibited Ang II-induced cardiac fibrosis in vivo, independent of anti-inflammatory effects.
- VPA suppressed Ang II-induced pericyte proliferation, migration, and transdifferentiation into myofibroblasts.
- VPA's inhibition of α-SMA expression was linked to reduced ERK phosphorylation, a process dependent on HDAC4 and modulated by PP2A/PP1 activity.
Conclusions:
- Pericyte differentiation into myofibroblasts is dependent on HDAC4 and requires ERK phosphorylation.
- The HDAC inhibitor VPA effectively blocks cardiac fibrosis by targeting pericyte transdifferentiation via the HDAC4/ERK pathway.
- These findings highlight a novel therapeutic strategy for myocardial fibrosis targeting HDACs.
Related Concept Videos
Amino Acid Biosynthetic Pathways
MAPK Signaling Cascades
GTPases and their Regulation
Large G-proteins,...
Respiratory Regulation of Acid-Base Balance
When carbon dioxide levels increase in the blood, more H+ and HCO3⁻ are...
Renal Regulation of Acid-Base Balance
In the kidneys, cells within the proximal convoluted tubules (PCT) and the collecting ducts secrete hydrogen ions (H+) into the tubular fluid. Specifically, in the PCT, Na+/H+ antiporters secrete H+ while reabsorbing Na+.
However, the intercalated cells in...
Master Transcription Regulators

